On 1/8/24, Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) stock enjoyed a major increase of 10.9%, closing at $39.48. Moreover, this advance was accompanied by exceptionally high trading volume at 314% of normal. Relative to the market the stock has been weak over the last nine months but has risen 27.4% during the last week.
Current PriceTarget Research Rating
ARWR’s future returns on capital are forecasted to be in line with the cost of capital. Accordingly, the company is expected to continue to be Value Creation neutral.
Arrowhead Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). This rating combines highly consistent signals from two proprietary PTR measures of a stock’s attractiveness. Arrowhead Pharmaceuticals has a very low Power Rating of 15 and a very low Appreciation Score of 3, resulting in the Lowest Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment